Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28

OCULAR THERAPEUTIX, INC

2025-FY EPS reported -$1.42 revenue$51,951,000

Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.
Net loss Q4 $64.7M ($0.29/shr), full year $265.9M ($1.42/shr); R&D spend rose to $50.8M.
SOL-1 Phase 3 wet AMD superiority data to be presented at Macula Society meeting Feb 25-28, 2026.
Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1, pending positive results and FDA interactions.
Cash $737.1M as of Dec 31, 2025; raised $475M in Sep 2025 equity offering; runway into 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.